17β-Estradiol overcomes human myeloma RPMI8226 cell suppression of growth, ALP activity, and mineralization in rat osteoblasts and improves RANKL/OPG balance in vitro

Leukemia Research

Volumn 33, Issue 9, 2009, Pages 1266-1271

  Li, Qiubai ^a   Yu, Ke ^a   Tian, Xiaolong ^a   Kong, Fancong ^a   You, Yong ^a   Chen, Zhichao ^a   Zou, Ping ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

17 Estradiol; Multiple myeloma; Osteoblast; RANKL OPG

Indexed keywords

ALKALINE PHOSPHATASE; ESTRADIOL; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PRIMER DNA; TNFSF11 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; BONE DISEASE; BONE MINERALIZATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLE MYELOMA; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; UPREGULATION; ANIMAL; CELL DIVISION; COCULTURE; CULTURE MEDIUM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALKALINE PHOSPHATASE; ANIMALS; BASE SEQUENCE; CALCIFICATION, PHYSIOLOGIC; CELL DIVISION; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; DNA PRIMERS; ESTRADIOL; HUMANS; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOPROTEGERIN; RANK LIGAND; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 67549118924     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.12.004     Document Type: Article

References (40)

1. Kyle R.A., and Rajkumar S.V. Multiple myeloma. N Engl J Med 351 (2004) 1860-1873
2. Yasui H., Hideshima T., Hamasaki M., et al. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood 106 (2005) 706-712
3. Giuliani N., Rizzoli V., and Roodman G. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 108 (2006) 3992-3996
4. Goodman G.D. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 32 (2004) 290-292
5. Barille-Nion S., and Bataille R. New insights in myeloma-induced osteolysis. Leuk Lymphoma 44 (2003) 1463-1467
6. Giuliani N., Colla S., and Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol 32 (2004) 685-691
7. Roodman G.D. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 32 (2004) 290-292
8. Sezer O. Myeloma bone disease. Hematology 10 (2005) 19-24
9. Berenson J.R., Lichtenstein A., Porter L., et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334 (1996) 488-493
10. Berenson J.R. Zoledronic acid in cancer patients with bone metastases: results of phase I and II trials. Semin Oncol 28 (2001) 25-34
11. Bataille R., Chappard D., Marcelli C., et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 88 (1991) 62-66
12. Taube T., Beneton M.N., McCloskey E.V., et al. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 49 (1992) 192-198
13. Yaccoby S., Ling W., Zhan F., et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109 (2007) 2106-2111
14. Standal T., Seidel C., Hjertner O., et al. Osteoprotegerin is bound internalized and degraded by multiple myeloma cells. Blood 100 (2002) 3002-3007
15. Lihua W., Xiaoyi Y., Kelly M., et al. Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3. J Biol Chem 276 (2001) 31839-31844
16. Richelson L.S., Wahner H.W., Melton L.J., et al. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 311 (1984) 1273-1275
17. Field C.S., Ory S.J., Wahner H.W., et al. Preventive effects of transdermal 17-β estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. Am J Obstet Gynecol 168 (1993) 114-121
18. Ettinger B. Use of low-dosage 17-β-estradiol for the prevention of osteoporosis. Clin Ther 15 (1993) 950-956
19. Ernst M., Schmid Ch., and Froesch E.R. Enhanced osteoblast proliferation and collagen gene expression by estradiol. PNAS 85 (1988) 2307-2310
20. Wong G., and Cohn D.V. Separation of parathyroid hormone and calcitonin-sensitive cells from non-responsive bone cells. Nature 252 (1974) 713-715
21. Saito Y., Yoshizawa T., Takizawa F., et al. A cell line with characteristics of the periodontal ligament fibroblasts is negatively regulated for mineralization and Runx2/Cbfa1/Osf2 activity, part of which can be overcome by bone morphogenetic protein-2. J Cell Sci 115 (2002) 4191-4200
22. Grimaud E., Soubigou L., Couillaud S., et al. Receptor activator of nuclear factor kappa B ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 163 (2003) 2021
23. Bataille R., Chappard D., Marcelli C., et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 7 (1989) 1909-1914
24. Bataille R., Chappard D., Marcelli C., et al. Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. Br J Haematol 76 (1990) 484-487
25. Hjorth-Hansen H., Seifert M.F., Borset M., et al. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res 14 (1999) 256-263
26. Evans C.E., Ward C., Rathour L., et al. Myeloma affects both the growth and function of human osteoblast-like cells. Clin Exp Metastasis 10 (1992) 33-38
27. Silvestris F., Cafforio P., Tucci M., et al. Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br J Haematol 122 (2003) 39-52
28. Tinhofer I., Biedermann R., Krismer M., et al. A role of TRAIL in killing osteoblasts by myeloma cells. FASEB J 20 (2006) 759-761
29. Giuliani N., Rizzoli V., and Roodman G.D. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 108 (2006) 3992-3996
30. Giuliani N., Colla S., Sala R., et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 100 (2002) 4615-4621
31. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
32. Giuliani N., Bataille R., Mancini C., et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98 (2001) 3527-3533
33. Terpos E., Szydlo R., Apperley J.F., et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102 (2003) 1064-1069
34. Pearse R.N., Sordillo E.M., Yaccoby S., et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98 (2001) 11581-11586
35. Vanderkerken K., De Leenheer E., Shipman C., et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 63 (2003) 287-289
36. Yaccoby S., Pearse R.N., Johnson C.L., et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116 (2002) 278-290
37. Oyajobi B.O., Anderson D.M., Traianedes K., et al. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 61 (2001) 2572-2578
38. Chen J.R., Shankar K., Nagarajan S., et al. Protective effects of estradiol on ethanol-induced bone loss involve inhibition of reactive oxygen species generation in osteoblasts and downstream activation of the extracellular signal-regulated kinase/signal transducer and activator of transcription 3/receptor activator of nuclear factor-kappaB ligand signaling cascade. J Pharmacol Exp Ther 324 (2008) 50-59
39. Sunil Srivastava, Gianluca Toraldo M., Neale Weitzmann, et al. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kB ligand (RANKL)-induced JNK activation. J Biol Chem 276 (2001) 8836-8840
40. Treon S.P., Teoh G., Urashima M., et al. Anti-estrogens induce apoptosis of multiple myeloma cells. Blood 92 (1998) 1749-1757